Literature DB >> 9492860

Higher incidence of diabetes in liver transplant recipients with hepatitis C.

H Knobler1, A Stagnaro-Green, S Wallenstein, M Schwartz, S H Roman.   

Abstract

We assessed the clinical and biochemical parameters associated with the development of posttransplantation diabetes (PTDM) in 52 liver transplant recipients followed up for 1 year. Diabetes was present before transplantation in 9.6% (5 of 52) of patients, and PTDM occurred in 23% (11 of 47) of the remaining liver transplant recipients. Of the 13 patients who had hepatitis C as the cause of their liver failure (HC-LD), 8 (62%) developed PTDM; of the 34 patients with other causes of liver failure, 3 (9%) developed PTDM (p < 0.001). Posttransplantation diabetes was also associated with the development of early posttransplantation hyperglycemia, a higher number of liver rejection episodes, and lower serum albumin levels at 6 months. The association of PTDM with HC-LD remained significant in a logistic regression model after adjustment for potential confounding variables. We conclude that PTDM is common in liver transplant recipients. Associated clinical parameters predictive of PTDM include a diagnosis of HC-LD before transplantation, the development of early hyperglycemia after transplantation, multiple episodes of posttransplantation liver rejection and low serum albumin levels at 6 months. The fact that HC-LD remained an independent risk factor for the development of PTDM may suggest a direct or immune-mediated pancreatic effect of the virus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9492860     DOI: 10.1097/00004836-199801000-00009

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  15 in total

1.  Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature.

Authors:  Silvia Fabiani; Poupak Fallahi; Silvia Martina Ferrari; Mario Miccoli; Alessandro Antonelli
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

2.  Update on the Management of Hepatitis C in Liver Transplant Recipients.

Authors:  David A Bobak; Gopal Yadavalli
Journal:  Curr Infect Dis Rep       Date:  2002-04       Impact factor: 3.725

3.  Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events.

Authors:  A B Jain; R Kashyap; J Rakela; T E Starzl; J J Fung
Journal:  Liver Transpl Surg       Date:  1999-03

Review 4.  Mechanisms and significance of liver steatosis in hepatitis C virus infection.

Authors:  Francesco Negro
Journal:  World J Gastroenterol       Date:  2006-11-14       Impact factor: 5.742

5.  HCV synergizes with body weight in the promotion of insulin resistance.

Authors:  A Delgado-Borrego; Y Kamegaya; S H Jordan; S Agrawal; C Valim; R T Chung
Journal:  J Viral Hepat       Date:  2011-02       Impact factor: 3.728

Review 6.  Hepatitis C and insulin action: An intimate relationship.

Authors:  Hilla Knobler; Stephen Malnick
Journal:  World J Hepatol       Date:  2016-01-18

7.  Glucose intolerance in Chinese patients with chronic hepatitis C.

Authors:  Liang-Kung Chen; Shinn-Jang Hwang; Shih-Tzer Tsai; Jiing-Chyuan Luo; Shou-Dong Lee; Full-Young Chang
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

8.  Hepatic dysfunction in kidney transplant recipients: prevalence and impact on graft and patient survival.

Authors:  Osama A Gheith; Mohamed A Saad; Ahmed A Hassan; Salem A-Eldeeb; Amgad E-El Agroudy; Hussein Sheashaa; Mohamed A Ghoneim
Journal:  Clin Exp Nephrol       Date:  2007-12-21       Impact factor: 2.801

9.  New onset diabetes after transplantation (NODAT): an overview.

Authors:  Phuong-Thu T Pham; Phuong-Mai T Pham; Son V Pham; Phuong-Anh T Pham; Phuong-Chi T Pham
Journal:  Diabetes Metab Syndr Obes       Date:  2011-05-09       Impact factor: 3.168

10.  Insulin resistance, steatosis and hepatitis C virus.

Authors:  Alessandra Mangia; Maria Ripoli
Journal:  Hepatol Int       Date:  2013-08-27       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.